Sarepta Therapeutics receives expanded approval for Elevidys

June 20, 2024 04:41 PM PDT | By Invezz

Sarepta Therapeutics receives expanded approval for Elevidys — Image source: Invezz

Why is it significant for Sarepta Therapeutics stock?

The FDA granted accelerated approval for a label expansion of “delandistrogene moxeparvovec” to include non-ambulatory patients on Thursday.

The decision is significant for individuals with DMD who have lost the ability to walk. Jerry Mendell – the co-inventor of Elevidys said in a press release today:

The expanded indication means clinicians now have a treatment option for the great majority of boys and young men living with Duchenne.

Sarepta Therapeutics stock is now up a whopping 80% versus the start of 2024.

Trading in Sarepta shares was temporarily halted

On Thursday, the U.S. regulator announced traditional approval for the treatment in ambulatory patients as well. According to Doug Ingram – the chief executive of Sarepta Therapeutics:

Today also stands as a watershed occasion for the promise of gene therapy and a win for science.

Both approvals apply to patients aged four years and older. The expanded approval is expected to materially impact the lives of individuals living with DMD, a rare genetic disorder that primarily affects boys, with an incidence rate of about one in every 3,300.

Trading in Sarepta shares was temporarily halted around 4:54 PM ET in anticipation of this news. Investors then cheered the news and pushed the stock up as trading resumed at 5:35 PM. SRPT recently joined the S&P MidCap 400.

Is there upside left in Sarepta stock?

Sarepta Therapeutics has already commenced a phase 3 post-marketing trial or the ENVISION study in non-ambulatory and older ambulatory patients of Duchenne to satisfy a condition for accelerated approval.

Note that Roche – a Swiss pharmaceutical giant is responsible for regulatory approvals as well as marketing of Elevidys outside of the United States. Jerry Mendall also said today:

This expansion speaks to the success of the science, the evidence and the improvements in the trajectory of the disease we have seen to date across studies.

Last month, SRPT reported its financial results for the first quarter that topped Street estimates. The drug developer earned 73 cents a share on $413.46 million in revenue versus 11 cents of per-share loss and $253.5 million in revenue in the same quarter of 2023.

Earlier in June, analysts at BMO Capital reiterated their “outperform” rating on Sarepta Therapeutics stock that has already touched their $170 price target announced at the time.

The post Sarepta Therapeutics receives expanded approval for Elevidys appeared first on Invezz

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.